Dr. Dipanjan Pan and Phil Robilotto of the University of Maryland, Baltimore, join Rich Bendis on BioTalk

By March 8, 2021BioTalk, News

Dr. Dipanjan Pan and Phil Robilotto of the University of Maryland, Baltimore, join BioTalk to discuss RNA Disease Diagnostics, UM Ventures, and the commercialization of new medical technologies

Listen via Apple http://apple.co/3bsUsda, Google http://bit.ly/38l26Vd , Spotify http://spoti.fi/38kp9zu, and TuneIN http://bit.ly/2MVFqDp.

 

Prof. Dipanjan Pan, MS, Ph.D., is an expert in nanomedicine, molecular imaging, drug delivery, and biosensing. He is presently a tenured Full Professor in Diagnostic Radiology & Nuclear Medicine, Pediatrics and Chemical, Biochemical and Environmental Engineering at the University of Maryland Baltimore School of Medicine and University of Maryland Baltimore County. Prior to moving to Maryland, he was a tenured Associate Professor and Associate Head of the department in Bioengineering and Materials Science and Engineering and Institute of Sustainability in Energy and Environment at the University of Illinois, Urbana-Champaign. He administratively directs the Nanofabrication and Characterization Core at CBOTH and a Director for the Investigational Probe Design Resources in Radiology.

He serves as study section review board member for NIH, CDMRP (DoD), NSF, and multiple review committee member for American Heart Association. In 2016 he received Nanomaterials Letter (NML) Researcher award, in 2017 a Young Innovator Award from Biomedical Engineering Society (BMES), and a Deans Award for Research Excellence in 2018. He is an elected fellow of the Royal Society of Chemistry, a Fellow of the American Heart Association, and an elected fellow of the American College of Cardiology. Professor Pan is an Associate Editor for WIRES Nanomedicine and Nanobiotechnology (Wiley) and an editorial advisory board member of Molecular Pharmaceutics (ACS).

Phil Robilotto, DO, MBA, is director of the technology development and commercialization program, University of Maryland (UM) Ventures, at the University of Maryland, Baltimore (UMB). Since joining UMB In 2012, Dr. Robilotto has grown UMB’s intellectual property, and licensing efforts, launched a new business venture initiative, and started an early-stage investment program that supports UMB start-ups.

Dr. Robilotto has over 20 years of clinical practice and pharmaceutical/biotechnology strategic planning and business development experience, most recently with Celera and DuPont Pharmaceuticals. He has led valuation and planning efforts for technology platforms and clinical-stage products and has successfully developed, negotiated, and executed collaborations across a broad range of life science-based technologies with a variety of commercial partners.

Dr. Robilotto is a licensed physician in the state of Maryland and received his DO from the Chicago College of Osteopathic Medicine. He also holds a BS in Biology from the College of William and Mary and an MBA from Duke University.

Click here to read the transcript.

Join our Mailing List